The Emerging Role of Gene Therapy in the Treatment of Cardiovascular Diseases

Critical Reviews in Clinical Laboratory Sciences

Volumn 40, Issue 5, 2003, Pages 499-545

  Barbato, Joel E ^a   Kibbe, Melina R ^b   Tzeng, Edith ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Gene therapy; Myocardial ischemia; Neointimal hyperplasia; Restenosis; Thrombosis; Transplant vasculopathy

Indexed keywords

ANGIOPOIETIN 1; CYCLOSPORIN; FIBROBLAST GROWTH FACTOR; HIRUDIN; NATRIURETIC PEPTIDE TYPE C; SCATTER FACTOR; TACROLIMUS; THROMBOPOIETIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; CARDIOVASCULAR DISEASE; CELL CYCLE; CLINICAL TRIAL; CYTOTOXICITY; GENE THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; THROMBOSIS; UNITED STATES; VASCULAR DISEASE;

ADENOVIRIDAE; UNIDENTIFIED RETROVIRUS;

EID: 0344945630     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360390250621     Document Type: Review

References (309)

1. Bittl JA. Advances in coronary angioplasty. N Engl J Med 1996; 335: 1290-1302.
2. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancer 2003; 361: 247-249.
3. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989; 244: 1342-1344.
4. Miller AD, Jolly DJ, Friedmann T, Verma IM. A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc Natl Acad Sci USA 1983; 80: 4709-4713.
5. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475-480.
6. Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953; 84: 570-573.
7. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
8. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 1997; 16: 2294-2306.
9. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-410.
10. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 1997; 40: 137-206.
11. Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol 1992; 158: 39-66.
12. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 2000; 97: 4802-4807.
13. Qian HS, Channon K, Neplioueva V, et al. Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. Circ Res 2001; 88: 911-917.
14. Nicklin SA, Baker AH. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr Gene Ther 2002; 2: 273-293.
15. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70: 6831-6838.
16. Perlman H, Liu H, Georganas C et al. Modifications in adenoviral coat fiber proteins and transcriptional regulatory sequences enhance transgene expression. J Rheumatol 2002; 29: 1593-1600.
17. Harvey BG, Maroni J, O'Donoghue KA, et al. Safety of local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15-63.
18. Mitani K, Kubo S. Adenovirus as an integrating vector. Curr Gene Ther 2002; 2: 135-144.
19. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-2245.
20. Newman KD, Dunn PF, Owens JW, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995; 96: 2955-2965.
21. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
22. Schulick AH, Vassalli G, Dunn PF, et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 1997; 99: 209-219.
23. Channon KM, Qian HS, Youngblood SA, et al. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function. Circ Res 1998; 82: 1253-1262.
24. Varmus H. Retroviruses. Science 1988; 240: 1427-1435.
25. Temin HM, Mizutani S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970; 226: 1211-1213.
26. Miller AD. Retroviral vectors. Curr Top Microbiol Immunol 1992; 158: 1-24.
27. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249: 1285-1288.
28. Flugelman MY, Jaklitsch MT, Newman KD, et al. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation 1992; 85: 1110-1117.
29. Feldman MD, Sun B, Koci BJ, et al. Stent-based gene therapy. J Long Term Eff Med Implants 2000; 10: 47-68.
30. Amsterdam A, Hopkins N. Retrovirus-mediated insertional mutagenesis in zebrafish. Methods Cell Biol 1999; 60: 87-98.
31. Check E. Cancer fears cast doubts on future of gene therapy. Nature 2003; 421: 678.
32. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adenoassociated virus 2 genome. J Virol 1983; 45: 555-564.
33. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther 1994; 1: 51-64.
34. Cheung AK, Hoggan MD, Hauswirth WW, Berns KI. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol 1980; 33: 739-748.
35. Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top Microbiol Immunol 1996; 218: 1-23.
36. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996; 7: 2101-2112.
37. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997; 389: 239-242.
38. Byun J, Heard JM, Huh JE, et al. Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. J Mol Cell Cardiol 2001; 33: 295-305.
39. Maeda Y, Ikeda U, Ogasawara Y, et al. Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. Cardiovasc Res 1997; 35: 514-521.
40. Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002; 8: 864-871.
41. Burton EA, Wechuck JB, Wendell SK, et al. Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 2001; 19: 358-377.
42. Quinonez R, Sutton RE. Lentiviral vectors for gene delivery into cells. DNA Cell Biol 2002; 21: 937-951.
43. Rizzuto G, Cappelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 1999; 96: 6417-6422.
44. Feigner JH, Kumar R, Sridhar CN, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994; 269: 2550-2561.
45. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280-285.
46. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene Ther 2002; 2: 183-194.
47. Lechardeur D, Sohn KJ, Haardt M, et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther 1999; 6: 482-497.
48. Oku N, Yamazaki Y, Matsuura M, et al. A novel non-viral gene transfer system, polycation liposomes. Adv Drug Deliv Rev 2001; 52: 209-218.
49. Nishikawa M, Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull 2002; 25: 275-283.
50. Hashida M, Nishikawa M, Yamashita F, Takakura Y. Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev 2001; 52: 187-196.
51. Matsumoto T, Komori K, Yonemitsu Y, et al. Hemagglutinating virus of Japan-liposome-mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. J Vasc Surg 1998; 27: 135-144.
52. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Novel and effective gene transfer technique for study of vascular renin angiotensin system. J Clin Invest 1993; 91: 2580-2585.
53. Liu Y, Mounkes LC, Liggitt HD, et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997; 15: 167-173.
54. Nabel EG, Pompili VJ, Plautz GE, Nabel GJ. Gene transfer and vascular disease. Cardiovasc Res 1994; 28: 445-455.
55. Nabel EG, Gordon D, Yang ZY, et al. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 1992; 3: 649-656.
56. Stewart MJ, Plautz GE, Del Buono L, et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 1992; 3: 267-275.
57. Bennett MR, Schwartz SM. Antisense therapy for angioplasty restenosis. Some critical considerations. Circulation 1995; 92: 1981-1993.
58. Marcus-Sekura CJ, Woemer AM, Shinozuka K, Zon G, Quinnan GV, Jr. Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages. Nucleic Acids Res 1987; 15: 5749-5763.
59. Kurreck J. Antisense technologies. Eur J Biochem 2003; 270: 1628-1644.
60. Morishita R, Gibbons GH, Ellison KE, et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994; 93: 1458-1464.
61. Cohen-Sacks H, Najajreh Y, Tchaikovski V, et al. Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther 2002; 9: 1607-1616.
62. Kawauchi M, Suzuki J, Morishita R, et al. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res 2000; 87: 1063-1068.
63. Kipshidze NN, Kim HS, Iversen P, et al. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol 2002; 39: 1686-1691.
64. Lowe HC, Chesterman CN, Khachigian LM. Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries. Thromb Haemost 2002; 87: 134-140.
65. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 6047-6052.
66. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351.
67. Wolff JA, Williams P, Acsadi G, et al. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 1991; 11: 474-485.
68. Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther 1993; 4: 151-159.
69. Danko I, Fritz JD, Jiao S, et al. Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Ther 1994; 1: 114-121.
70. Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv 2002; 55: 392-397.
71. Feldman LJ, Steg G. Optimal techniques for arterial gene transfer. Cardiovasc Res 1997; 35: 391-404.
72. Fernandez-Ortiz A, Meyer BJ, Mailhac A, et al. A new approach for local intravascular drug delivery. Iontophoretic balloon. Circulation 1994; 4: 1518-1522.
73. Hong MK, Wong SC, Farb A, et al. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery. Coron Artery Dis 1993; 4: 1023-1027.
74. Lambert CR, Leone JE, Rowland SM. Local drug delivery catheters: functional comparison of porous and microporous designs. Coron Artery Dis 1993; 4: 469-475.
75. Tsui LV, Zayek N, Frey D, et al. Stability of adenoviral vectors following catheter delivery. Mol Ther 2001; 3: 122-125.
76. Marshall DJ, Palasis M, Lepore JJ, Leiden JM. Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: an important determinant of the efficiency of cardiovascular gene transfer. Mol Ther 2000; 1: 423-429.
77. Laitinen M, Yla-Herttuala S. Adventitial gene transfer to arterial wall. Pharmacol Res 1998; 37: 251-254.
78. Tahlil O, Brami M, Feldman LJ, Branellec D, Steg PG. The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res 1997; 33: 181-187.
79. Palasis M, Luo Z, Barry JJ, Walsh K. Analysis of adenoviral transport mechanisms in the vessel wall and optimization of gene transfer using local delivery catheters. Hum Gene Ther 2000; 11: 237-246.
80. Amabile PG, Waugh JM, Lewis TN, et al. High-efficiency endovascular gene delivery via therapeutic ultrasound. J Am Coll Cardiol 2001; 37: 1975-1980.
81. Beeri R, Guerrero JL, Supple G, et al. New efficient catheter-based system for myocardial gene delivery. Circulation 2002; 106: 1756-1759.
82. Taniyama Y, Tachibana K, Hiraoka K, et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002; 105: 1233-1239.
83. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stem placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
84. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-495.
85. Panetta CJ, Miyauchi K, Berry D, et al. A tissue-engineered stent for cell-based vascular gene transfer. Hum Gene Ther 2002; 13: 433-441.
86. Dichek DA, Neville RF, Zwiebel JA, et al. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989; 80: 1347-1353.
87. Flugelman MY, Virmani R, Leon MB, Bowman RL, Dichek DA. Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to flow in vitro. Circ Res 1992; 70: 348-354.
88. Pakkanen TM, Laitinen M, Hippelainen M, et al. Periadventitial lacZ gene transfer to pig carotid arteries using a biodegradable collagen collar or a wrap of collagen sheet with adenoviruses and plasmid-liposome complexes. J Gene Med 2000; 2: 52-60.
89. Airenne KJ, Hiltunen MO, Turunen MP, et al. Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery. Gene Ther 2000; 7: 1499-1504.
90. Van Belle E, Maillard L, Rivard A, et al. Effects of poloxamer 407 on transfection time and percutaneous adenovirus-mediated gene transfer in native and stented vessels. Hum Gene Ther 1998; 9: 1013-1024.
91. Laitinen M, Pakkanen T, Donetti E, et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses. pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 1997; 8: 1645-1650.
92. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol 2000; 190: 300-309.
93. FitzGibbon GM, Leach AJ, Keon WJ, Burton JR, Kafka HP. Coronary bypass graft fate. Angiographic study of 1,179 vein grafts early, one year, and five years after operation. J Thorac Cardiovasc Surg 1986; 91: 773-778.
94. Acar C, Jebara VA, Portoghese M, et al. Revival of the radial artery for coronary artery bypass grafting. Ann Thorac Surg 1992; 54: 652-659.
95. Grondin CM, Campeau L, Lesperance J, et al. Atherosclerotic changes in coronary vein grafts six years after operation. Angiographic aspect in 110 patients. J Thorac Cardiovasc Surg 1979; 77: 24-31.
96. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94: 35-43.
97. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-784.
98. Yang Z, Simari RD, Tanner F, et al. Gene transfer approaches to the regulation of vascular cell proliferation. Semin Interv Cardiol 1996; 1: 181-184.
99. Steg PG, Tahlil O, Aubailly N, et al. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation 1997; 96: 408-411.
100. Harrell RL, Rajanayagam S, Doanes AM, et al. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation 1997; 96: 621-627.
101. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995; 96: 2260-2268.
102. Qin ZH, Wang Y, Nakai M, Chase TN. Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum. Mol Pharmacol 1998; 53: 33-42.
103. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-1683.
104. Yoshimura S, Morishita R, Hayashi K, et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 2001; 8: 1635-1642.
105. Nakamura T, Morishita R, Asai T, et al. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 2002; 9: 488-494.
106. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-1498.
107. McCarthy M. Molecular decoy may keep bypass grafts open. Lancet 2001; 358: 1703.
108. Ehsan A, Mann MJ, Dell'Acqua G, et al. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation 2002; 105: 1686-1692.
109. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269.
110. Luscher TF, Diederich D, Siebenmann R, et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 1988; 319: 462-467.
111. Yang ZH, von Segesser L, Bauer E, et al. Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res 1991; 68: 52-60.
112. Tarry WC, Makhoul RG. L-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscler Thromb 1994; 14: 938-943.
113. Davies MG, Kim JH, Dalen H, et al. Reduction of experimental vein graft intimal hyperplasia and preservation of nitric oxide-mediated relaxation by the nitric oxide precursor L-arginine. Surgery 1994; 116: 557-568.
114. McNamara DB, Bedi B, Aurora H, et al. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1993; 193: 291-296.
115. Lee JS, Adrie C, Jacob HJ, et al. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ Res 1996; 78: 337-342.
116. Groves PH, Banning AP, Penny WJ, et al. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc Res 1995; 30: 87-96.
117. Von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-1141.
118. Chen AF, O'Brien T, Katusic ZS. Transfer and expression of recombinant nitric oxide synthase genes in the cardiovascular system. Trends Pharmacol Sci 1998; 19: 276-286.
119. Kullo IJ, Schwartz RS, Pompili VJ, et al. Expression and function of recombinant endothelial NO synthase in coronary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2405-2412.
120. Varenne O, Pislaru S, Gillijns H, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998; 98: 919-926.
121. Shears LL, Kibbe MR, Murdock AD, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998; 187: 295-306.
122. Muhs A, Heublein B, Schletter J, et al. Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation. Hum Gene Ther 2003; 14: 375-383.
123. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990; 86: 1690-1697.
124. Ohno N, Itoh H, Ikeda T, et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105: 1623-1626.
125. Hayashi K, Nakamura S, Morishita R, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000; 7: 1664-1671.
126. Asahara T, Chen D, Tsunami Y, et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 1996; 94: 3291-3302.
127. Ueno H, Li JJ, Masuda S, et al. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 1997; 17: 2453-2460.
128. Hayashi S, Watanabe N, Nakazawa K, et al. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation 2000; 102: 1710-1717.
129. Furukawa Y, Matsumori A, Ohashi N, et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 1999; 84: 306-314.
130. Mori E, Komori K, Yamaoka T, et al. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 2002; 105: 2905-2910.
131. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996; 2: 293-298.
132. Luo Z, Sata M, Nguyen T, et al. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 1999; 99: 1776-1779.
133. Maillard L, Van Belle E, Tio FO, et al. Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries. Gene Ther 2000; 7: 1353-1361.
134. Bashir R, Vale PR, Isner JM, Losordo DW. Angiogenic gene therapy: pre-clinical studies and phase I clinical data. Kidney Int 2002; 61: 110-114.
135. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364.
136. Rissanen TT, Vajanto I, Yla-Herttuala S. Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb-on the way to the clinic. Eur J Clin Invest 2001; 31: 651-666.
137. Ito WD, Arras M, Scholz D, et al. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am J Physiol 1997; 273: H1255-H1265.
138. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996; 2: 534-539.
139. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998; 98: 2081-2087.
140. Aoki M, Morishita R, Taniyama Y, Kaneda Y, Ogihara T. Therapeutic angiogenesis induced by hepatocyte growth factor, potential gene therapy for ischemic diseases. J Atheroscler Thromb 2000; 7: 71-76.
141. Aoki M, Morishita R, Taniyama Y, et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 2000; 7: 417-427.
142. Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8: 181-189.
143. Ahmet I, Sawa Y, Iwata K, Matsuda H, Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: a novel gene therapy for cardiomyopathy. J Thorac Cardiovasc Surg 2002; 124: 957-963.
144. Smith RS, Jr., Lin KF, Agata J, Chao L, Chao J. Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 2002; 22: 1279-1285.
145. Shyu KG, Wang MT, Wang BW, et al. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 2002; 54: 576-583.
146. Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000; 102: 2255-2261.
147. Emanueli C, Salis MB, Chao J, et al. Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice. Arterioscler Thromb Vasc Biol 2000; 20: 1459-1466.
148. Emanueli C, Minasi A, Zacheo A, et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 2001; 103: 125-132.
149. Hou D, Maclaughlin F, Thiesse M, et al. Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery. Catheter Cardiovasc Interv 2003; 58: 207-211.
150. Brizzi MF, Battaglia E, Montrucchio G, et al. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res 1999; 84: 785-796.
151. Semenza GL. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 2001; 108: 39-40.
152. Matsunaga T, Warltier DC, Weihrauch DW, et al. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000; 102: 3098-3103.
153. Laitinen M, Zachary I, Breier G, et al. VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries. Hum Gene Ther 1997; 8: 1737-1744.
154. Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998; 252: 743-746.
155. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662-670.
156. Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994; 89: 2183-2189.
157. Mack CA, Patel SR, Schwarz EA, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thor Card Surg 1998; 115: 168-176.
158. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
159. Laitinen M, Hartikainen J, Hiltunen MO, et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000; 11: 263-270.
160. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103: 2138-2143.
161. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000; 31: S1-S296.
162. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281-3290.
163. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-374.
164. Isner JM, Walsh K, Symes J, et al. Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Circulation 1995; 91: 2687-2692.
165. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28: 964-973.
166. Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg 1998; 176: 26S-38S.
167. Nissen NN, Polverini PJ, Koch AE, et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445-1552.
168. Lawrence WT, Diegelmann RF. Growth factors in wound healing. Clin Dermatol 1994; 12: 157-169.
169. Robson MC, Mustoe TA, Hunt TK, The future of recombinant growth factors in wound healing. Am J Surg 1998; 176: 80S-82S.
170. Greenhalgh DG. The role of growth factors in wound healing. J Trauma 1996; 41: 159-167.
171. Ghazizadeh S, Taichman LB. Virus-mediated gene transfer for cutaneous gene therapy. Hum Gene Ther 2000; 11: 2247-2251.
172. Vogel JC. Nonviral skin gene therapy. Hum Gene Ther 2000; 11: 2253-2259.
173. Tyrone JW, Mogford JE, Chandler LA, et al. Collagen-embedded platelet-derived growth factor DNA plasmid promotes wound healing in a dermal ulcer model. J Surg Res 2000; 93: 230-236.
174. Liechty KW, Nesbit M, Herlyn M, et al. Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J Invest Dermatol 1999; 113: 375-383.
175. Breitbart AS, Mason JM, Urmacher C, et al. Gene-enhanced tissue engineering: applications for wound healing using cultured dermal fibroblasts transduced retrovirally with the PDGF-B gene. Ann Plast Surg 1999; 43: 632-639.
176. Sun L, Xu L, Chang H, et al. Transfection with aFGF cDNA improves wound healing. J Invest Dermatol 1997; 108: 313-318.
177. Romano DP, Mangoni A, Zambruno G, et al. Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Ther 2002; 9: 1271-1277.
178. Yamasaki K, Edington HD, McClosky C, et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998; 101: 967-971.
179. Andree C, Swain WF, Page CP, et al. In vivo transfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci USA 1994; 91: 12188-12192.
180. Rivard A, Fabre JE, Silver M, et al. Age-dependent impairment of angiogenesis. Circulation 1999; 99: 111-120.
181. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-a-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000; 102: 185-190.
182. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154: 355-363.
183. Couffinhal T, Silver M, Kearney M, et al. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/-mice. Circulation 1999; 99: 3188-3198.
184. Duan J, Murohara T, Ikeda H, et al. Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: nitric oxide-dependent mechanism. Circulation 2000; 102: III370-III376.
185. Duan J, Murohara T, Ikeda H, et al. Hyperhomocysteinemia impairs angiogenesis in response to hindlimb ischemia. Arterioscler Thromb Vasc Biol 2000; 20: 2579-2585.
186. Rekhter MD, Simari RD, Work CW, et al. Gene transfer into normal and atherosclerotic human blood vessels. Circ Res 1998; 82: 1243-1252.
187. Van Belle E, Rivard A, Chen D, et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997; 96: 2667-2674.
188. Taniyama Y, Morishita R, Hiraoka K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001; 104: 2344-2350.
189. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation 2000; 102: E73-E86.
190. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-1123.
191. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-429.
192. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000; 6: 1102-1103.
193. Lee RJ, Springer ML, Blanco-Bose WE, et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.
194. Banai S, Jaklitsch MT, Casscells W, et al. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res 1991; 69: 76-85.
195. Yin G, Liu W, An P, et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002; 5: 547-554.
196. Frankish H. Researchers target tumour blood vessels with antiangiogenic gene therapy. Lancet 2002; 359: 2256.
197. Kim JM, Ho SH, Park EJ, et al. Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum 2002; 46: 793-801.
198. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-840.
199. Masaki I, Yonemitsu Y, Yamashita A, et al. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 2002; 90: 966-973.
200. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
201. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92: 905-909.
202. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461.
203. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Christiansen CL, Gurwitz JH. Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old. Arch Intern Med 2002; 162: 561-568.
204. Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 2000; 101: 2239-2246.
205. Zoldhelyi P, McNatt J, Shelat HS, et al. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000; 101: 289-295.
206. Golino P, Cirillo P, Calabro' P, et al. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. J Am Coll Cardiol 2001; 38: 569-576.
207. Singh R, Pan S, Mueske CS, et al. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res 2001; 89: 71-76.
208. Zoldhelyi P, Chen ZQ, Shelat HS, McNatt JM, Willerson JT. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci USA 2001; 98: 4078-4083.
209. Ohlin AK, Marlar RA. Thrombomodulin gene defects in families with thromboembolic disease - a report on four families. Thromb Haemost 1999; 81: 338-344.
210. Nawa K, Itani T, Ono M, et al. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation. Thromb Haemost 1992; 67: 366-370.
211. Waugh JM, Yuksel E, Li J, et al. Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 1999; 84: 84-92.
212. Whittle BJ, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 1978; 16: 373-388.
213. Hara S, Morishita R, Tone Y, et al. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem Biophys Res Commun 1995; 216: 862-867.
214. Gershlick AH, Spriggins D, Davies SW, et al. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br Heart J 1994; 71: 7-15.
215. Yamada M, Numaguchi Y, Okumura K, et al. Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries. Arterioscler Thomb Vasc Biol 2002; 22: 256-262.
216. Numaguchi Y, Naruse K, Harada M, et al. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thomb Vasc Biol 1999; 19: 727-733.
217. Harada M, Toki Y, Numaguchi Y, et al. Prostacyclin synthase gene transfer inhibits neointimal formation in rat balloon-injured arteries without bleeding complications. Cardiovasc Res 1999; 43: 481-491.
218. Zoldhelyi P, McNatt J, Xu XM, et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 1996; 93: 10-17.
219. Kuo MD, Waugh JM, Yuksel E, et al. 1998 ARRS President's Award. The potential of in vivo vascular tissue engineering for the treatment of vascular thrombosis: a preliminary report. American Roentgen Ray Society. AJR Am J Roentgenol 1998; 171: 553-558.
220. Waugh JM, Kattash M, Li J, et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA 1999; 96: 1065-1070.
221. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827-834.
222. Yeung AC, Davis SF, Hauptman PJ, et al. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. J Heart Lung Transplant 1995; 14: S215-S220.
223. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12: 334-340.
224. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc 1987; 19: 19-25.
225. Billingham ME. Graft coronary disease: the lesions and the patients. Transplant Proc 1989; 21: 3665-3666.
226. Gao SZ, Schroeder JS, Alderman EL, et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987; 76: V56-V61.
227. Furukawa Y, Matsumori A, Hirozane T, Sasayama S. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 1996; 93: 333-339.
228. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969-975.
229. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 1993; 328: 164-170.
230. Ardehali A, Laks H, Drinkwater DC, Ziv E, Drake TA. Vascular cell adhesion molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy. Circulation 1995; 92: 450-456.
231. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts: association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant Proc 1995; 27: 1939-1940.
232. Posten RS, Ennen M, Pollard J, et al. Ex vivo gene therapy prevents chronic graft vascular disease in cardiac allografts. J Thorac Cardiovasc Surg 1998; 116: 386-396.
233. Sai S, Iwata A, Thomas R, Allen MD. Vascular cell adhesion molecule-1 up-regulation and phenotypic modulation of vascular smooth muscle cells predate mononuclear infiltration in transplant arteriopathy. J Thorac Cardiovasc Surg 2001; 122: 508-517.
234. Suzuki J, Isobe M, Aikawa M, et al. Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts. A study in rat and monkey models. Circulation 1996; 94: 1118-1124.
235. Rekhter MD, Shah N, Simari RD, et al. Graft permeabilization facilitates gene therapy of transplant arteriosclerosis in a rabbit model. Circulation 1998; 98: 1335-1341.
236. Faulk WP, Labarrere CA, Nelson DR, Pitts D. Hemostasis, fibrinolysis, and natural anticoagulation in transplant vascular sclerosis. J Heart Lung Transplant 1995; 14: S158-S164.
237. Faulk WP, Labarrere CA, Nelson DR, Pitts D. Coronary artery disease in cardiac allografts: association with arterial antithrombin. Transplant Proc 1995; 27: 1944-1946.
238. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts: association with depleted arteriolar tissue plasminogen activator. Transplant Proc 1995; 27: 1941-1943.
239. Scholl FG, Sen L, Drinkwater DC, et al. Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis. J Heart Lung Transplant 2001; 20: 322-329.
240. Vinten-Johansen J, Zhao ZQ, Sato H. Reduction in surgical ischemic-reperfusion injury with adenosine and nitric oxide therapy. Ann Thorac Surg 1995; 60: 852-857.
241. Kurose I, Wolf R, Grisham MB, Granger DN. Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 1994; 74: 376-382.
242. Pinsky DJ, Oz MC, Koga S, et al. Cardiac preservation is enhanced in a heterotopic rat transplant model by supplementing the nitric oxide pathway. J Clin Invest 1994; 93: 2291-2297.
243. Shears LL, Kawaharada N, Tzeng E, et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 1997; 100: 2035-2042.
244. Lee PC, Wang ZL, Qian S, et al. Endothelial nitric oxide synthase protects aortic allografts from the development of transplant arteriosclerosis. Transplantation 2000; 69: 1186-1192.
245. Yap J, O'Brien T, Pellegrini C, et al. Distribution and function of recombinant endothelial nitric oxide synthase in transplanted hearts. Cardiovasc Res 1999; 42: 720-727.
246. Iwata A, Sai S, Moore M, et al. Gene therapy of transplant arteriopathy by liposome-mediated transfection of endothelial nitric oxide synthase. J Heart Lung Transplant 2000; 19: 1017-1028.
247. Brauner R, Wu L, Laks H, et al. Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts: method and efficacy of adenovirus-mediated transduction. J Thorac Cardiovasc Surg 1997; 113: 1059-1066.
248. Lee J, Laks H, Drinkwater DC, et al. Cardiac gene transfer by intracoronary infusion of adenovirus vector-mediated reporter gene in the transplanted mouse heart. J Thorac Cardiovasc Surg 1996; 111: 246-252.
249. Suzuki J, Izawa A, Morishita R, et al. Prevention of cardiac allograft arteriopathy by antisense Cdc2 kinase oligonucleotide. Transplant Proc 1999; 31: 867-868.
250. Tsukioka K, Suzuki J, Fujimori M, et al. Expression of matrix metalloproteinases in cardiac allograft vasculopathy and its attenuation by anti MMP-2 ribozyme gene transfection. Cardiovasc Res 2002; 56: 472-478.
251. Yoon YS, Murayama T, Gravereaux E, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 2003; 111: 717-725.
252. Watanabe Y, Chu Y, Andresen JJ, et al. Gene transfer of extracellular superoxide dismutase reduces cerebral vasospasm after subarachnoid hemorrhage. Stroke 2003; 34: 434-440.
253. Chu Y, Iida S, Lund DD, et al. Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: role of heparin-binding domain. Circ Res 2003; 92: 461-468.
254. Bai H, Morishita R, Kida I, et al. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther 1998; 5: 761-769.
255. Condorelli G, Aycock JK, Frati G, Napoli C. Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice. FASEB J 2001; 15: 2162-2170.
256. McArthur JG, Qian H, Citron D, et al. p27-p16 Chimera: a superior antiproliferative for the prevention of neointimal hyperplasia. Mol Ther 2001; 3: 8-13.
257. Tsui LV, Camrud A, Mondesire J, et al. p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Cric Res 2001; 89: 323-328.
258. Iaccarino G, Smithwick LA, Lefkowitz RJ, Koch WJ. Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis. Proc Natl Acad Sci USA 1999; 96: 3945-3950.
259. Zhu NL, Wu L, Liu PX, et al. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 1997; 96: 628-635.
260. Xu F, Prescott MF, Liu PX, et al. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int J Mol Med 2001; 8: 19-30.
261. George SJ, Angelini GD, Capogrossi MC, Baker AH. Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther 2001; 8: 668-676.
262. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478.
263. Yasumoto H, Kim S, Zhan Y, et al. Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats. Gene Ther 2001; 8: 1682-1689.
264. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867-877.
265. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 1998; 5: 1552-1560.
266. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296-304.
267. Shears LL, Kibbe MR, Murdock AD, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 1998; 187: 295-306.
268. Cable DG, Caccitolo JA, Caplice N, et al. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 1999; 100: II392-II396.
269. Chen L, Daum G, Forough R, et al. Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ Res 1998; 82: 862-870.
270. Ohno N, Itoh H, Ikeda T, et al. Accelerated reendothelialization with suppressed thrombogenic properly and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 2002; 105: 1623-1626.
271. Ueno H, Haruno A, Morisaki N, et al. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation 1997; 96: 2272-2279.
272. Qian JY, Haruno A, Asada Y, et al. Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Cric Res 2002; 91: 1063-1069.
273. Usui M, Egashira K, Ohtani K, et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 2002; 16: 1838-1840.
274. Lombardi JV, Naji M, Larson RA, et al. Adenoviral mediated uteroglobin gene transfer to the adventitia reduces arterial intimal hyperplasia. J Surg Res 2001; 99: 377-380.
275. Laukkanen MO, Kivela A, Rissanen T, et al. Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2002; 106: 1999-2003.
276. Stephan D, San H, Yang ZY, et al. Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon. Mol Med 1997; 3: 593-599.
277. Ding H, Wang R, Marcel R, Fisher DZ. Adenovirus-mediated expression of a truncated PDGF-beta receptor inhibits thrombosis and neointima formation in an avian arterial injury model. Thromb Haemost 2001; 86: 914-922.
278. Asahara T, Bauters C, Pastore C, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995; 91: 2793-2801.
279. Hiltunen MO, Laitinen M, Turunen MP, et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2000; 102: 2262-2268.
280. Asahara T, Chen D, Tsurumi Y, et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 1996; 94: 3291-3302.
281. Hayashi K, Nakamura S, Morishita R, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther 2000; 7: 1664-1671.
282. Hanna AK, Fox JC, Neschis DG, et al. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg 1997; 25: 320-325.
283. Yamamoto K, Morishita R, Tomita N, et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 2000; 102: 1308-1314.
284. Yin X, Yutani C, Ikeda Y, et al. Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries. Cardiovasc Res 2002; 56: 454-463.
285. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
286. Gunn J, Holt CM, Francis SE, et al. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res 1997; 80: 520-531.
287. Bennett MR, Anglin S, McEwan JR, et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-828.
288. Shi Y, Fard A, Galeo A, et al. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 1994; 90: 944-951.
289. Tulis DA, Mnjoyan ZH, Schiesser RL, et al. Adenoviral gene transfer of fortilin attenuates neointima formation through suppression of vascular smooth muscle cell proliferation and migration. Circulation 2003; 107: 98-105.
290. Kume M, Komori K, Matsumoto T, et al. Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation 2002; 105: 1226-1232.
291. Ahn JD, Morishita R, Kaneda Y, et al. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia. Gene Ther 2002; 9: 1682-1692.
292. Maillard L, Van Belle E, Smith RC, et al. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc Res 1997; 35: 536-546.
293. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267: 518-522.
294. Smith RC, Wills KN, Antelman D, et al. Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation 1997; 96: 1899-1905.
295. Claudio PP, Fratta L, Farina F, et al. Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty. Circ Res 1999; 85: 1032-1039.
296. Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999; 230: 466-470.
297. Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999; 68: 830-836.
298. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102: 965-974.
299. Sarkar N, Ruck A, Kallner G, et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: angiogenic gene therapy. J Intern Med 2001; 250: 373-381.
300. Simovic D, Isner JM, Ropper AH, Pieczek A, Weinberg DH. Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia. Arch Neurol 2001; 58: 761-768.
301. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104: 753-755.
302. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012-2018.
303. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930-936.
304. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-1297.
305. Shyu KG, Chang H, Wang BW, Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 2003; 114: 85-92.
306. Yan ZQ, Yokota T, Zhang W, Hansson GK. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ Res 1996; 79: 38-44.
307. Rade JJ, Cheung M, Miyamoto S, Dichek DA. Retroviral vector-mediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins. Gene Ther 1999; 6: 385-392.
308. Carmeliet P, Stassen JM, Van V, I, et al. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thromboly sis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1- overexpressing mice. Blood 1997; 90: 1527-1534.
309. Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996; 93: 301-309.